compound semaglutide ending The Shortage Is Ending: What's Next For Compounded Drugs? FDA announces ban for compounded

Synapse targets the structural foundation of cognitive function: the density and quality of synaptic connections between neurons

Market Overview: The GLP-1 Receptor Agonist Market size was valued at USD 28,600.00 million in 2018 to USD 53,158.08 million in 2024 and is anticipated to reach USD 2,04,613.75 million by 2032, at a CAGR of 18.40% during the forecast period

GLP-1 receptor agonists (like semaglutide) and tirzepatide already show benefits in NAFLD/NASH

1 Introduction Type 2 diabetes has become a major global public health challenge

Pushing the boundaries of molecular representation for drug discovery with the graph attention mechanism